Patents by Inventor Stephen Todd Meyer

Stephen Todd Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF
    Publication number: 20250002486
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a cyclic sulfonamide RNR inhibitor disclosed herein.
    Type: Application
    Filed: September 15, 2022
    Publication date: January 2, 2025
    Inventors: Anthony B. PINKERTON, Jacques MAUGER, Yen Pham Hong TRUONG, Rachelle Janette ELSDON, Stephen Todd MEYER
  • SULFAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF
    Publication number: 20240425490
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a sulfamide RNR inhibitor disclosed herein.
    Type: Application
    Filed: September 15, 2022
    Publication date: December 26, 2024
    Inventors: Anthony B. PINKERTON, Jacques MAUGER, Yen Pham Hong TRUONG, Rachelle Janette ELSDON, Stephen Todd MEYER
  • RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF
    Publication number: 20240158383
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a of RNR inhibitor disclosed herein.
    Type: Application
    Filed: March 1, 2022
    Publication date: May 16, 2024
    Inventors: Anthony B. PINKERTON, Jacques MAUGER, Stephen Todd MEYER
  • CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF
    Publication number: 20230310423
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.
    Type: Application
    Filed: June 1, 2023
    Publication date: October 5, 2023
    Inventors: Anthony B. PINKERTON, Stephen Todd MEYER, Jacques MAUGER, Yen Pham Hong TRUONG, Rachelle Janette ELSDON
  • Checkpoint kinase 1 (CHK1) inhibitors and uses thereof
    Patent number: 11707462
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.
    Type: Grant
    Filed: August 29, 2022
    Date of Patent: July 25, 2023
    Assignee: BOUNDLESS BIO, INC.
    Inventors: Anthony B. Pinkerton, Stephen Todd Meyer, Jacques Mauger, Yen Pham Hong Truong, Rachelle Janette Elsdon
  • CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF
    Publication number: 20230026313
    Abstract: Provided herein are compounds and methods for the treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Chk1 inhibitor disclosed herein.
    Type: Application
    Filed: August 29, 2022
    Publication date: January 26, 2023
    Inventors: Anthony B. PINKERTON, Stephen Todd MEYER, Jacques MAUGER, Yen Pham Hong TRUONG, Rachelle Janette ELSDON
  • 3-aryl-2H-pyrazolo[4,3-b]pyridine compounds and their use as AMPA receptor modulators
    Patent number: 10100045
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: October 16, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Brian Ngo Laforteza, Brad M. Savall, Warren Stanfield Wade, Stephen Todd Meyer, Márió Gyuris
  • Fused bicylic pyridine compounds and their use as AMPA receptor modulators
    Patent number: 10087185
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: October 2, 2018
    Assignee: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Márió Gyuris, Brian Ngo Laforteza, Terry Patrick Lebold, Stephen Todd Meyer, Suchitra Ravula, Brad M. Savall, Brock T. Shireman, Warren Stanfield Wade, János Gerencsér
  • 3-ARYL-2H-PYRAZOLO[4,3-b]PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS
    Publication number: 20180111925
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Application
    Filed: October 23, 2017
    Publication date: April 26, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Brian Ngo Laforteza, Brad M. Savall, Warren Stanfield Wade, Stephen Todd Meyer, Márió Gyuris
  • FUSED BICYLIC PYRIDINE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS
    Publication number: 20180111933
    Abstract: Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).
    Type: Application
    Filed: October 23, 2017
    Publication date: April 26, 2018
    Applicant: Janssen Pharmaceutica NV
    Inventors: Michael K. Ameriks, Márió Gyuris, Brian Ngo Laforteza, Terry Patrick Lebold, Stephen Todd Meyer, Suchitra Ravula, Brad M. Savall, Brock T. Shireman, Warren Stanfield Wade, János Gerencsér